AEON Biopharma, Inc.: Daewoong Co., Ltd amends Schedule 13D stake filing
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
Daewoong Co., Ltd. amended its Schedule 13D stake filing for AEON Biopharma, Inc., according to SEC accession 0001213900-26-117881. The filing updates the Korean pharmaceutical company's previously reported beneficial ownership position in the biopharma issuer. Schedule 13D amendments are required when a holder's ownership or intent changes materially, making the disclosure a signal of Daewoong's evolving posture toward its AEON stake. The amendment itself does not specify a change in share count or percentage in the headline data. Investors should watch for further 13D amendments or Form 4 filings to confirm whether Daewoong's position or intentions have shifted.
Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13D's report. It can get details wrong, so check the source.
Named in this story
Daewoong Co., Ltd, AEON Biopharma, Inc.